gms | German Medical Science

65th Annual Meeting of the German Association for Medical Informatics, Biometry and Epidemiology (GMDS), Meeting of the Central European Network (CEN: German Region, Austro-Swiss Region and Polish Region) of the International Biometric Society (IBS)

06.09. - 09.09.2020, Berlin (online conference)

Efficiencies through integrated research platforms: Considerations on sharing of active data

Meeting Abstract

Search Medline for

  • Tobias Mielke - Janssen Cilag GmbH, Neuss, Germany

Deutsche Gesellschaft für Medizinische Informatik, Biometrie und Epidemiologie. 65th Annual Meeting of the German Association for Medical Informatics, Biometry and Epidemiology (GMDS), Meeting of the Central European Network (CEN: German Region, Austro-Swiss Region and Polish Region) of the International Biometric Society (IBS). Berlin, 06.-09.09.2020. Düsseldorf: German Medical Science GMS Publishing House; 2021. DocAbstr. 293

doi: 10.3205/20gmds106, urn:nbn:de:0183-20gmds1062

Published: February 26, 2021

© 2021 Mielke.
This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 License. See license information at http://creativecommons.org/licenses/by/4.0/.


Outline

Text

Platform studies are considered to increase both, operational and statistical efficiency. Operational efficiency is achieved through a flexible study design which allows to test multiple interventions in possibly multiple sub-populations under one overarching master protocol. The design process of a platform study will typically be of higher complexity and longer in duration as compared to designing a single standard clinical study. Operational efficiencies of the platform approach increase with an increasing number of tested interventions in the study, due to decreasing required time for study start up, internal governance and regulatory interactions for each new intervention. Larger statistical efficiency as compared to standard clinical study designs is achieved by sharing of control data. Instead of running 4 studies with a 1:1 randomization, one study with 2:1:1:1:1 randomization would require less patients in total and on the control group to reach the same power for each individual active arm. Depending on the objectives of the platform study and the similarity of interventions under investigation, additional statistical efficiency can be generated by combining data from the study interventions. This may be of particular relevance in Phase 2 platform studies with the aim to investigate new mechanisms of action and to establish signs of activity for the tested interventions in the new mechanisms. Optimized contrast testing approaches (e.g. MCPMod) have been introduced as an efficient alternative to standard pairwise comparisons in multi-armed dose-finding studies. Generalizations of the contrast testing approach to allow efficient decision making in platform studies will be introduced in this presentation. Connections, benefits and limitations as compared to the simple sharing of control data and the more complex hierarchical modelling of treatment effects will be discussed.

The authors declare that they have no competing interests.

The authors declare that an ethics committee vote is not required.


References

1.
Saville BR, Berry SM. Efficiencies of platform clinical trials: A vision of the future. Clin Trials. 2016 Jun;13(3):358-66. DOI: 10.1177/1740774515626362 External link
2.
Bretz F, Pinheiro JC, Branson M. Combining multiple comparisons and modeling techniques in dose-response studies. Biometrics. 2005 Sep;61(3):738-48. DOI: 10.1111/j.1541-0420.2005.00344.x External link
3.
Tang R, Shen J, Yuan Y. ComPAS: A Bayesian drug combination platform trial design with adaptive shrinkage. Stat Med. 2019 Mar;38(7):1120-1134. DOI: 10.1002/sim.8026 External link